IDEAYA Biosciences, a pharmaceutical company based in the United States, specializes in oncology-focused precision medicine. With an ESG score of 33.7, it is considered high risk. IDEAYA is dedicated to developing targeted therapeutics for patients through molecular diagnostics. Their product candidate, IDE196, targets genetically defined cancers with GNAQ or GNA11 gene mutations using protein kinase C (PKC) inhibitors.